115 related articles for article (PubMed ID: 8910634)
1. K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient.
Ito K; Watanabe K; Nasim S; Sasano H; Sato S; Yajima A; Silverberg SG; Garrett CT
Gynecol Oncol; 1996 Nov; 63(2):238-46. PubMed ID: 8910634
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium.
Mizuuchi H; Nasim S; Kudo R; Silverberg SG; Greenhouse S; Garrett CT
Cancer Res; 1992 May; 52(10):2777-81. PubMed ID: 1581890
[TBL] [Abstract][Full Text] [Related]
3. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L
Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651
[TBL] [Abstract][Full Text] [Related]
4. Studies on ras oncogene activation in endometrial carcinoma.
Fujimoto I; Shimizu Y; Hirai Y; Chen JT; Teshima H; Hasumi K; Masubuchi K; Takahashi M
Gynecol Oncol; 1993 Feb; 48(2):196-202. PubMed ID: 8428691
[TBL] [Abstract][Full Text] [Related]
5. K-ras activation in premalignant and malignant epithelial lesions of the human uterus.
Enomoto T; Inoue M; Perantoni AO; Buzard GS; Miki H; Tanizawa O; Rice JM
Cancer Res; 1991 Oct; 51(19):5308-14. PubMed ID: 1913654
[TBL] [Abstract][Full Text] [Related]
6. Mutations of the Ki-ras oncogene in carcinoma of the endometrium.
Caduff RF; Johnston CM; Frank TS
Am J Pathol; 1995 Jan; 146(1):182-8. PubMed ID: 7856726
[TBL] [Abstract][Full Text] [Related]
7. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
8. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
9. K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients.
Conzelmann M; Linnemann U; Berger MR
Int J Oncol; 2004 Jun; 24(6):1537-44. PubMed ID: 15138598
[TBL] [Abstract][Full Text] [Related]
10. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
11. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer.
Lachance JA; Everett EN; Greer B; Mandel L; Swisher E; Tamimi H; Goff B
Gynecol Oncol; 2006 Jun; 101(3):470-5. PubMed ID: 16413048
[TBL] [Abstract][Full Text] [Related]
12. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic lymph nodal and plexus micrometastases detected by enriched polymerase chain reaction and nonradioisotopic single-strand conformation polymorphism analysis: a new predictive factor for recurrent pancreatic carcinoma.
Tamagawa E; Ueda M; Takahashi S; Sugano K; Uematsu S; Mukai M; Ogata Y; Kitajima M
Clin Cancer Res; 1997 Nov; 3(11):2143-9. PubMed ID: 9815608
[TBL] [Abstract][Full Text] [Related]
14. K-ras mutation in tamoxifen-related endometrial polyps.
Hachisuga T; Miyakawa T; Tsujioka H; Horiuchi S; Emoto M; Kawarabayashi T
Cancer; 2003 Nov; 98(9):1890-7. PubMed ID: 14584071
[TBL] [Abstract][Full Text] [Related]
15. ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum.
Garrett AP; Ng SW; Muto MG; Welch WR; Bell DA; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Apr; 77(1):105-11. PubMed ID: 10739698
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality.
Al-Mulla F; Going JJ; Sowden ET; Winter A; Pickford IR; Birnie GD
J Pathol; 1998 Jun; 185(2):130-8. PubMed ID: 9713338
[TBL] [Abstract][Full Text] [Related]
17. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients.
Cuatrecasas M; Erill N; Musulen E; Costa I; Matias-Guiu X; Prat J
Cancer; 1998 Mar; 82(6):1088-95. PubMed ID: 9506354
[TBL] [Abstract][Full Text] [Related]
18. Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma.
Duggan BD; Felix JC; Muderspach LI; Tsao JL; Shibata DK
Cancer Res; 1994 Mar; 54(6):1604-7. PubMed ID: 8137266
[TBL] [Abstract][Full Text] [Related]
19. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.
Petrowsky H; Sturm I; Graubitz O; Kooby DA; Staib-Sebler E; Gog C; Köhne CH; Hillebrand T; Daniel PT; Fong Y; Lorenz M
Eur J Surg Oncol; 2001 Feb; 27(1):80-7. PubMed ID: 11237496
[TBL] [Abstract][Full Text] [Related]
20. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
